Loading…
Loading…
ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026.
On October 21, 2026, TransMedics Group Inc (TMDX) shares fell by 3.1%, bringing the current price to $72.40. This decline is notable within a 52-week range of $
TransMedics Group (NASDAQ: TMDX - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability. Institutional and Insider Ownership 99.7% of TransMedics
On October 01, 2026, TransMedics Group Inc (TMDX) shares fell 5.8%, closing at $78.64. The stock's performance over the past year has been challenging, with a 5
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 26, 2026Shareholders are encouraged to contact the
Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible for out-of-pocket payment of our legal fees or expenses.
TransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) shares shot up 4.5% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $89.15 and last traded at $89.7060. 308,922 shares traded hands during trading, a decline of 70% from the average daily volume of 1,029,492
These companies' sell-offs may have gone too far.